Flu season is officially underway, and health experts are predicting a particularly severe outbreak this year. With the spread of influenza A (H3N2) expected...
Skyhawk Therapeutics has received a significant funding boost of $2 billion from Merck KGaA, marking a pivotal moment in the development of RNA therapeutics....